FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913238977> ?p ?o ?g. }

• W2913238977 endingPage "4077" @default.
• W2913238977 startingPage "4077" @default.
• W2913238977 abstract "Abstract Introduction TP53 mutations in relapsed cases with pediatric acute lymphoblastic leukemia have been implicated in poor clinical outcomes. However, the prevalence and clinical significance of TP53 mutations at diagnosis have not been fully investigated. Such knowledge is essential for the care of patients, because treatment intensity is tailored to predictive prognosis, where increased attention has been directed toward de-escalation of treatment for the problem of long term effects and second malignancies in childhood cancer survivors. Methods Mutation status of TP53 was detected by targeted-capture sequencing of TP53 coding regions in 1,003 children with B-precursor ALL who had been treated in either of the two prospective clinical trials, JACLS (Japan Association of Childhood Leukemia Study) ALL-02 and TCCSG (Tokyo Children's Cancer Study Group) L04-16. Detection of common fusion genes, including BCR-ABL, ETV6-RUNX1, MLL-AF4, MLL-ENL, MLL-AF9, and TCF3-PBX1, were performed using qPCR assays. We designed SNP baits to analyze copy number status of chromosome 17, and also captured 662 probes tiling the entire IgH enhancer locus to identify IGH-DUX4 rearrangement. Result In total, 36 different non-silent coding TP53 mutations were identified in 30 (3%) patients, including 22 missense, 7 frameshift indel, 5 in-frame indel, and 2 nonsense mutations. All missense mutations were found in the core DNA-binding domain (n=21), except for one mutation, which affected the tetramerization motif. Variant allele frequencies (VAF) of TP53 mutations varied from 3% to 97% with 14 mutations showing < 10% VAFs. Showing a significant correlation with mutated TP53 (Odds ratio 20: 95%CI 6.4-61, P<0.001), loss of heterozygosity affecting the TP53 locus was observed in 11 (37%) cases and caused by del(17p) in most cases (n=10). We next evaluated clinical features of TP53-mutated cases. TP53 was most frequently mutated in Hypodiploid ALL (33% n=3), followed by MLL rearrangement (12% n=4), IGH-DUX4 (9% n=5), Others (3% n=8), TCF3-PBX1 (2% n=2), Hyperdiploid (2% n=6), and ETV6-RUNX1 (n=2 0.9%). TP53 mutations were not associated with age or white blood cell count at diagnosis. However, significantly more patients were categorized into National Cancer Institute (NCI) high risk (HR) category (Odds ratio 2.4: 95%CI 1.1-5.3, P = 0.03) and TP53 mutation was associated with a significantly shorter overall survival (OS) among NCI-HR patients (n = 16; HR for death, 6.3; 95% CI, 3.1-13; P<0.001). Five-year OS of NCI-HR patients with TP53 mutations was 44%, suggesting that early treatment intensification or alternative treatment strategies are warranted for these patients. TP53 mutations were also associated with a shorter OS in MLL rearrangement and IGH-DUX4 ALL. Particularly, 67% (n=4/6) of cases with any cause of death harbored TP53 mutation in IGH-DUX4 ALL. In contrast, TP53 mutation was not associated with shorter overall survival in NCI-SR cases. In Hyperdiploid ALL, 5 out of 6 cases with TP53 mutations were categorized into the NCI-SR category and were all alive. Prognostic impact of TP53 mutation was also investigated using recursive partitioning to generate a hierarchical prognostic model for OS by incorporating genetic subgroups and the NCI risk criteria. This model also demonstrated that the NCI risk criteria was the most important prognostic variable and TP53 mutation was used for stratification of patients only in the NCI-HR category. Conclusion TP53 mutations at diagnosis are common in Hypodiploid ALL and also found in a substantial fraction of MLL rearrangement and IGH-DUX4 ALL, where the mutations predict a poor prognosis. TP53 mutation is also found in NCI-SR cases but may not be associated with poor prognosis. Figure. Figure. Disclosures No relevant conflicts of interest to declare." @default.
• W2913238977 created "2019-02-21" @default.
• W2913238977 creator A5002554232 @default.
• W2913238977 creator A5009065536 @default.
• W2913238977 creator A5019098042 @default.
• W2913238977 creator A5024179981 @default.
• W2913238977 creator A5025014885 @default.
• W2913238977 creator A5027219029 @default.
• W2913238977 creator A5028379115 @default.
• W2913238977 creator A5030942209 @default.
• W2913238977 creator A5031014013 @default.
• W2913238977 creator A5035340824 @default.
• W2913238977 creator A5037869187 @default.
• W2913238977 creator A5038183052 @default.
• W2913238977 creator A5040001548 @default.
• W2913238977 creator A5040079244 @default.
• W2913238977 creator A5040777714 @default.
• W2913238977 creator A5041204580 @default.
• W2913238977 creator A5042588749 @default.
• W2913238977 creator A5044213915 @default.
• W2913238977 creator A5049230435 @default.
• W2913238977 creator A5049685204 @default.
• W2913238977 creator A5050295936 @default.
• W2913238977 creator A5050620740 @default.
• W2913238977 creator A5052266116 @default.
• W2913238977 creator A5058882740 @default.
• W2913238977 creator A5063421369 @default.
• W2913238977 creator A5066055908 @default.
• W2913238977 creator A5073119979 @default.
• W2913238977 creator A5076753985 @default.
• W2913238977 creator A5078968582 @default.
• W2913238977 creator A5079530630 @default.
• W2913238977 creator A5079998695 @default.
• W2913238977 creator A5084056429 @default.
• W2913238977 creator A5084551717 @default.
• W2913238977 creator A5088167618 @default.
• W2913238977 creator A5089636566 @default.
• W2913238977 date "2018-11-29" @default.
• W2913238977 modified "2023-10-18" @default.
• W2913238977 title "The Prognostic Value of TP53 Mutations Depends on Clinical Backgrounds in Pediatric Patients with Acute Lymphoblastic Leukemia" @default.
• W2913238977 doi "https://doi.org/10.1182/blood-2018-99-115617" @default.
• W2913238977 hasPublicationYear "2018" @default.
• W2913238977 type Work @default.
• W2913238977 sameAs 2913238977 @default.
• W2913238977 citedByCount "0" @default.
• W2913238977 crossrefType "journal-article" @default.
• W2913238977 hasAuthorship W2913238977A5002554232 @default.
• W2913238977 hasAuthorship W2913238977A5009065536 @default.
• W2913238977 hasAuthorship W2913238977A5019098042 @default.
• W2913238977 hasAuthorship W2913238977A5024179981 @default.
• W2913238977 hasAuthorship W2913238977A5025014885 @default.
• W2913238977 hasAuthorship W2913238977A5027219029 @default.
• W2913238977 hasAuthorship W2913238977A5028379115 @default.
• W2913238977 hasAuthorship W2913238977A5030942209 @default.
• W2913238977 hasAuthorship W2913238977A5031014013 @default.
• W2913238977 hasAuthorship W2913238977A5035340824 @default.
• W2913238977 hasAuthorship W2913238977A5037869187 @default.
• W2913238977 hasAuthorship W2913238977A5038183052 @default.
• W2913238977 hasAuthorship W2913238977A5040001548 @default.
• W2913238977 hasAuthorship W2913238977A5040079244 @default.
• W2913238977 hasAuthorship W2913238977A5040777714 @default.
• W2913238977 hasAuthorship W2913238977A5041204580 @default.
• W2913238977 hasAuthorship W2913238977A5042588749 @default.
• W2913238977 hasAuthorship W2913238977A5044213915 @default.
• W2913238977 hasAuthorship W2913238977A5049230435 @default.
• W2913238977 hasAuthorship W2913238977A5049685204 @default.
• W2913238977 hasAuthorship W2913238977A5050295936 @default.
• W2913238977 hasAuthorship W2913238977A5050620740 @default.
• W2913238977 hasAuthorship W2913238977A5052266116 @default.
• W2913238977 hasAuthorship W2913238977A5058882740 @default.
• W2913238977 hasAuthorship W2913238977A5063421369 @default.
• W2913238977 hasAuthorship W2913238977A5066055908 @default.
• W2913238977 hasAuthorship W2913238977A5073119979 @default.
• W2913238977 hasAuthorship W2913238977A5076753985 @default.
• W2913238977 hasAuthorship W2913238977A5078968582 @default.
• W2913238977 hasAuthorship W2913238977A5079530630 @default.
• W2913238977 hasAuthorship W2913238977A5079998695 @default.
• W2913238977 hasAuthorship W2913238977A5084056429 @default.
• W2913238977 hasAuthorship W2913238977A5084551717 @default.
• W2913238977 hasAuthorship W2913238977A5088167618 @default.
• W2913238977 hasAuthorship W2913238977A5089636566 @default.
• W2913238977 hasConcept C104317684 @default.
• W2913238977 hasConcept C138626823 @default.
• W2913238977 hasConcept C143998085 @default.
• W2913238977 hasConcept C2780833115 @default.
• W2913238977 hasConcept C29906990 @default.
• W2913238977 hasConcept C501734568 @default.
• W2913238977 hasConcept C502942594 @default.
• W2913238977 hasConcept C54355233 @default.
• W2913238977 hasConcept C71924100 @default.
• W2913238977 hasConcept C75563809 @default.
• W2913238977 hasConcept C86803240 @default.
• W2913238977 hasConceptScore W2913238977C104317684 @default.
• W2913238977 hasConceptScore W2913238977C138626823 @default.
• W2913238977 hasConceptScore W2913238977C143998085 @default.
• W2913238977 hasConceptScore W2913238977C2780833115 @default.
• W2913238977 hasConceptScore W2913238977C29906990 @default.
• W2913238977 hasConceptScore W2913238977C501734568 @default.

• next